Table 2.
Univariate and Multivariate Analysis of Overall Survival.
| Univariate analysis | Multivariate analysis | |||
|---|---|---|---|---|
| Overall survival, months | P a | HR (95% CI) | P b | |
| Group (FOLFOX-HAIC/Sorafenib) | 17.1 vs 9.07 | <.001 | 0.29 (0.19-0.44) | <.001 |
| Age, years (≤50/>50) | 9.4 vs 10.63 | .88 | ||
| Sex (male/female) | 10.17 vs 10.63 | .56 | ||
| ECOG-PS (0/1) | 11.1 vs 9.47 | .16 | ||
| HBV infection (yes/no) | 10.63 vs 7.83 | .36 | ||
| Tumor size, cm (≤10/>10) | 10.93 vs 9.7 | .67 | ||
| Tumor number (single/multiple) | 7.83 vs 10.93 | .26 | ||
| PVTT (absence/presence) | 12.4 vs 8.53 | .02 | 0.49 (0.31-0.77) | .002 |
| AFP, ng/mL (≤1000/>1000) | 10.97 vs 9.4 | .09 | 0.71 (0.47-1.07) | .1 |
| mALBI (1/2a/2b) | 11.1 vs 9.7 vs 7.83 | .27 | ||
| Child-Pugh score (5 vs 6) | 10.73 vs 9.13 | .12 | ||
Abbreviations: FOLFOX, oxaliplatin, 5-fluorouracil and leucovorin; HR, hazard ratio; CI, confidence interval; ECOG, Eastern Cooperative Oncology Group; HBV, hepatitis B virus; PVTT, portal vein tumor thrombus; AFP, alpha-fetoprotein; mALBI, modified albumin-bilirubin grade.
a
P value was calculated with a 2-sided log-rank test. Any factors that were statistically significant at P less than 10% in the univariate analysis were candidates for entry into a multivariable Cox analysis.
b
P value was calculated by multivariable Cox proportional-hazards analysis.